Literature DB >> 2338681

Quality of life as a vital clinical sign.

B W Kong1, J Clive, S H Kong.   

Abstract

Hypertension is a significant public health problem in the United States. Despite this, many patients fail to seek or comply with treatment, owing to potential adverse effects on the patient's quality of life (QOL). This paper reports on the development and evaluation of an instrument for evaluating the QOL of black patients who are being treated for hypertension. The scale proved highly reliable (Cronbach's alpha = 0.949), and correlated well with lengthier instruments for assessing QOL. Results are presented from administration of the questionnaire to 998 patients.

Entities:  

Mesh:

Year:  1990        PMID: 2338681

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  5 in total

1.  Assessing the responsiveness of a quality-of-life instrument and the measurement of symptom severity in essential hypertension.

Authors:  M C Reilly; A S Zbrozek
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

Review 2.  Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension.

Authors:  M I Wilde; H M Bryson; K L Goa
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

3.  Psychometric properties of the VSQLQ in black patients with mild hypertension. Vital Signs Quality of Life Questionnaire.

Authors:  N K Leidy; J K Schmier; A E Bonomi; M Legro; T Zyczynski; B W Kong
Journal:  J Natl Med Assoc       Date:  2000-12       Impact factor: 1.798

4.  A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension.

Authors:  P Chan; B Tomlinson; Y J Chen; J C Liu; M H Hsieh; J T Cheng
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

Review 5.  Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.